University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
J Autism Dev Disord. 2019 Nov;49(11):4595-4602. doi: 10.1007/s10803-019-04173-z.
Using a dataset involving 415 individuals with irritability, aggression, agitation and self-injury (IAAS) behaviors from the fragile X syndrome (FXS) FORWARD database, we describe the psychopharmacologic management of IAAS and features of the population of persons with FXS treated with drug therapy for IAAS. Among those with FXS exhibiting IAAS, individuals with FXS receiving drug treatment of IAAS were older, more predominantly male, have more significant intellectual disability, more like to have comorbid autism, hyperarousal, and social impairments. The most commonly utilized medications for IAAS in FXS are antipsychotic medications, specifically aripiprazole and risperidone (37% and 27%, respectively). The majority of subjects (63%) experienced no side effects noted from the use of their psychopharmacologic medications.
利用来自脆性 X 综合征(FXS)FORWARD 数据库的涉及 415 名具有烦躁、攻击、激动和自残(IAAS)行为的个体的数据集,我们描述了 IAAS 的精神药理学管理以及接受药物治疗 IAAS 的 FXS 患者人群的特征。在表现出 IAAS 的 FXS 个体中,接受 IAAS 药物治疗的 FXS 个体年龄更大,更男性化,智力残疾更严重,更可能伴有自闭症、过度觉醒和社交障碍。FXS 中最常用于 IAAS 的药物是抗精神病药物,特别是阿立哌唑和利培酮(分别为 37%和 27%)。大多数受试者(63%)在使用精神药理学药物时没有注意到任何副作用。